Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam

被引:44
作者
van der Cruijsen-Koeter, IW
van der Kwast, TH
Schröder, FH
机构
[1] Univ Med Ctr Rotterdam, Erasmus MC, Dept Urol, NL-3000 CA Rotterdam, Netherlands
[2] Univ Med Ctr Rotterdam, Erasmus MC, Dept Pathol, NL-3000 CA Rotterdam, Netherlands
关键词
D O I
10.1093/jnci/djg057
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The interval cancer rate is an important parameter for determining the sensitivity of a screening procedure and the screening interval. We evaluated the time and mechanism of detection and the stage distribution of interval prostate cancers diagnosed during a 4-year screening interval. Methods: We determined the rate of interval cancers and the sensitivity of the screening protocol (involving prostate-specific antigen, digital rectal and transrectal ultrasound examinations) in a cohort of 17 226 men (8350 on the screened arm, 8876 on the control arm) enrolled consecutively on the European Randomized Study of Screening for Prostate Cancer-Rotterdam. Men on the screened arm received a first screen between October 1993 and December 1996 and a scheduled second screen 4 years later. Prostate cancers detected in men enrolled on the control arm over the same 4-year period and, between screens, in men on the screened arm, were identified by linkage to the Dutch national cancer registry. Results: During the first screen, 412 prostate cancers were detected. During the subsequent 4-year period, 135 cancers were diagnosed in men in the control arm and 25 cancers were diagnosed in men in the screened arm. Seven of the 25 cancers were diagnosed in men who had refused a recommended biopsy at their initial screen. Of the remaining 18 cancers, all were classified as stage T1A-C or T2A and none were poorly differentiated or metastatic. The rate of interval cancers relative to the number of cancers in the control group was 18.5% (25/135), or 13.3% (18/135), if the seven who refused an initial biopsy were excluded. The sensitivity of the screening protocol was 79.8% when considering all 25 interval cancers and 85.5% when considering 18 interval cancers. Conclusion: The interval cancer rate with a 4-year screening interval was low, confirming that the screening procedure has a high sensitivity and that the 4-year screening interval is reasonable.
引用
收藏
页码:1462 / 1466
页数:5
相关论文
共 23 条
[1]   Lead-time in prostate cancer screening (Finland) [J].
Auvinen, A ;
Määttänen, L ;
Stenman, UH ;
Tammela, T ;
Rannikko, S ;
Aro, J ;
Juusela, H ;
Hakama, M .
CANCER CAUSES & CONTROL, 2002, 13 (03) :279-285
[2]   Prostate specific antigen testing and digital rectal examination before and during a randomized trial of screening for prostate cancer:: European randomized study of screening for prostate cancer, Rotterdam [J].
Beemsterboer, PMM ;
de Koning, HJ ;
Kranse, R ;
Trienekens, PH ;
van der Maas, PJ ;
Schröder, FH .
JOURNAL OF UROLOGY, 2000, 164 (04) :1216-1220
[3]   COMPUTER-SIMULATION OF THE PROBABILITY OF DETECTING LOW-VOLUME CARCINOMA OF THE PROSTATE WITH 6 RANDOM SYSTEMATIC CORE BIOPSIES [J].
DANESHGARI, F ;
TAYLOR, GD ;
MILLER, GJ ;
CRAWFORD, ED .
UROLOGY, 1995, 45 (04) :604-609
[4]   Large-scale randomized prostate cancer screening trials:: Program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial [J].
de Koning, HJ ;
Auvinen, A ;
Sanchez, AB ;
da Silva, FC ;
Ciatto, S ;
Denis, L ;
Gohagan, JK ;
Hakama, M ;
Hugosson, J ;
Kranse, R ;
Nelen, V ;
Prorok, PC ;
Schröder, FH .
INTERNATIONAL JOURNAL OF CANCER, 2002, 97 (02) :237-244
[5]   PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/ml [J].
Djavan, B ;
Zlotta, A ;
Kratzik, C ;
Remzi, M ;
Seitz, C ;
Schulman, CC ;
Marberger, M .
UROLOGY, 1999, 54 (03) :517-522
[6]   Lead times and overdetection due to prostate-specific antigen screening:: Estimates from the European randomized study of screening for prostate cancer [J].
Draisma, G ;
Boer, R ;
Otto, SJ ;
van der Cruijsen, IW ;
Damhuis, RAM ;
Schröder, FH ;
de Koning, HJ .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (12) :868-878
[7]   Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate [J].
Eskew, LA ;
Bare, RL ;
McCullough, DL .
JOURNAL OF UROLOGY, 1997, 157 (01) :199-202
[8]   LATENT CARCINOMA OF THE PROSTATE [J].
FRANKS, LM .
JOURNAL OF PATHOLOGY AND BACTERIOLOGY, 1954, 68 (02) :603-&
[9]   A PROSPECTIVE EVALUATION OF PLASMA PROSTATE-SPECIFIC ANTIGEN FOR DETECTION OF PROSTATIC-CANCER [J].
GANN, PH ;
HENNEKENS, CH ;
STAMPFER, MJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (04) :289-294
[10]   The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: History, organization, and status [J].
Gohagan, JK ;
Prorok, PC ;
Hayes, RB ;
Kramer, BS .
CONTROLLED CLINICAL TRIALS, 2000, 21 (06) :251S-272S